## **Supplementary Information**

Nalmefene non-enantioselectively targets myeloid differentiation protein 2 and inhibits Toll-like receptor 4 signaling: wet-lab techniques and *in silico* simulations

Xiaozheng Zhang<sup>a</sup>, Hongshuang Wang<sup>b,\*</sup>, Yibo Wang<sup>b</sup>, Hongyuan Li<sup>b</sup>, SiruWu<sup>b,c</sup>, Jingwei Gao<sup>b,c</sup>, Tianshu Zhang<sup>b</sup>, Jun Xie<sup>a,\*</sup>, Xiaohui Wang<sup>b,c,\*</sup>

<sup>a</sup>Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan, Shanxi, 030001, China

<sup>b</sup>Laboratory of Chemical Biology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China

<sup>c</sup>Department of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, 230026, China

\* Corresponding author E-mail: <u>hongshuang.wang@ciac.ac.cn</u> E-mail: <u>junxie@sxmu.edu.cn</u> E-mail: <u>xiaohui.wang@ciac.ac.cn</u>;

**Table S1** MM/PBSA derived binding free energies (kcal/mol) for nalmefene binding to murine MD-2

	$\Delta \; E_{vdW}$	$\Delta E_{ele}$	$\Delta G_{sol-polar}$	$\Delta G_{sol-nonpolar}$	$\Delta G_{\text{binding}}$
(+)-nalmefene	-47.3±0.3	-1.2±0.1	5.2±0.1	24.8±0.2	-18.4±0.4
(-)-nalmefene	-43.2±0.4	-1.1±0.1	4.7±0.1	21.9±0.2	-17.8±0.4
(+)-naltrexone <sup>a</sup>	-44.5±0.1	-1.6±0.1	5.5±0.1	23.7±0.1	-16.9±0.2ª
(-)-naltrexone <sup>a</sup>	-47.8±0.3	-1.4±0.1	6.6±0.1	24.6±0.2	-18.0±0.3ª

Numbers after  $\pm$  present standard errors;

<sup>a</sup>SeeRef.16

Table S2. The decomposition of per-residue binding free energies (kcal/mol) o	f							
nalmefene and naltrexone binding to murine MD-2								

		Compound			
Residue	(+)-nalmefene	(-)-nalmefene	(+)-naltrexone <sup>a</sup>	(-)-naltrexone <sup>a</sup>	
Trp23		-2.3±0.4			
Ser48		-1.5±0.9	-1.5±.9		
Ile52		-1.6±0.3	-1.4±0.3	$-2.3\pm0.5$	
Val61	-1.1±0.2	-1.2±0.3	-1.6±0.4	-1.2±0.3	
Phe76	-2.3±0.7		-2.1±0.4	-1.7±0.4	
Leu78	-2.0±0.3	-1.3±0.3		-1.4±0.3	
Ile80					
Arg90	-1.1±0.2				
Glu92	-1.3±0.3		$-1.5\pm0.4$	-1.5±0.7	
Phe119	-2.6±0.4	-1.8±0.3	$-2.2\pm0.4$	-1.5±0.4	
Phe121	-1.3±0.4	-1.6±0.4	-1.5±0.5	-1.1±0.3	
Ala135	-1.4±0.4				
Cys133	-1.0±0.3	-1.0±0.3			
Leu149	-1.2±0.3				
Phe151	-3.1±0.4	-3.1±0.4	-2.7±0.5	-2.2±0.5	

Numbers after ± present standard error <sup>a</sup>SeeRef.16







Figure S1. Structures of (+)-naltrexone and (-)-naltrexone.




**Figure S2.** Alignment of docking poses from Autodock Vina (green stick) and Glide XP (cyan stick). Human MD-2 is shown as green cartoon.




**Figure S3.** Time evolution of Cα RMSDs of human MD-2 (A) and ligand (B) during MD simulation Black and red colors indicate (+)-nalmefene and (-)-nalmefene, respectively.



**Figure S4.** Time evolution of Cα RMSD of murine MD-2 (A) and ligand (B) during MD simulation. Black and red colors indicate (+)-nalmefene and (-)-nalmefene, respectively.



**Figure S5**. Overlap of the conformation of MD-2 ((A-B), human MD-2; (C-D), murine MD-2) bound to LPS ((A-B), PDB ID: 2E59; (C-D), PDB ID: 2Z64); both in cyan) with the representative structures of MD-2 interacted with nalmefene ((A, C), (+)-nalmefene; (B, D), (-)-nalmefene) with the lowest energy (in green).



**Figure S6.** The main dimerization interface between the the F126 loop of MD-2 and TLR4\* that is from the adjacent copy of TLR4-MD-2. Overlap of the conformation of active MD-2 (cyan) with the representative structures of MD-2 interacted with (+)-nalmefene (red) (A) and (-)-nalmefene (red) (B), with the lowest energy. TLR4\* was shown as green cartoon, the key residues in dimerization interface were shown as stick. Binding of nalmefene to MD-2 abolishes most of the key interactions between MD-2 F126 loop and TLR4\*.




Figure S7. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of (-)-nalmefene




Figure S8. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of (+)-nalmefene